title: Diabetes News.
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Abigail E
authors.initials: AE
authors.lastname: Dove
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Payal H
authors.initials: PH
authors.lastname: Marathe
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Helen X
authors.initials: HX
authors.lastname: Gao
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Odeh
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Kelly L
authors.initials: KL
authors.lastname: Close
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use; D003226:Congresses as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D004763:Glucagon-Like Peptides / Q000627:therapeutic use; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use; D000099194:Semaglutide
chemical_list: D001559:Benzhydryl Compounds; D000077270:Exenatide; D004763:Glucagon-Like Peptides; D005960:Glucosides; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000099194:Semaglutide; C529054:dapagliflozin